Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain
Copyright © 2022 Garcia de Lucas, Miramontes-González, Avilés-Bueno, Jiménez-Millán, Rivas-Ruiz and Pérez-Belmonte..
Objectives: To investigate the use of once-weekly semaglutide in a real population of people with type 2 diabetes mellitus (T2DM) in three Spanish hospitals.
Method: An observational, retrospective and multicenter clinical study was designed that included 166 participants with T2DM, distinguishing between a group naïve to GLP-1RA (n=72) and another switching from another GLP-1RA (n=94), all managed in the outpatient clinical setting. The primary endpoint was the change in HbA1c from baseline to the end of the study. The secondary endpoints included changes in body weight and the proportion of people with T2DM, achieving HbA1c <7.0% and body weight loss >5%.
Results: After 24 months of follow-up, the reductions in HbA1c were -0.91 ± 0.7% (p<0.001) in the total cohort, -1.13 ± 1.38% (p<0.019) for GLP-1RA-naïve participants, and -0.74 ± 0.9% (p<0.023) for GLP-1RA-experienced participants. Body weight reductions were -12.42 ± 9.1% in GLP-1RA-naïve participants vs. -7.65 ± 9.7% in GLP-1RA-experienced participants (p<0.001). In the total cohort, 77.1% reached the objective of an HbA1c level <7%, and 12.7% reached between 7.1% and 7.5%. Additionally, 66.9% achieved a weight reduction ≥5%. Of all cohort, 90% received 1 mg of semaglutide once a week. The reported adverse events were consistent with the known safety profile of semaglutide.
Conclusions: In routine clinical practice in Spain, the use of semaglutide once a week was associated with statistically significant and clinically relevant improvements in HbA1c and body weight in a wide range of adults with T2DM, without notable adverse effects, which supports real-world use.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Frontiers in endocrinology - 13(2022) vom: 27., Seite 995646 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Garcia de Lucas, Maria Dolores [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.10.2022 Date Revised 07.12.2022 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.3389/fendo.2022.995646 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347026125 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347026125 | ||
| 003 | DE-627 | ||
| 005 | 20231226032841.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fendo.2022.995646 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1156.xml |
| 035 | |a (DE-627)NLM347026125 | ||
| 035 | |a (NLM)36187123 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Garcia de Lucas, Maria Dolores |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.10.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Garcia de Lucas, Miramontes-González, Avilés-Bueno, Jiménez-Millán, Rivas-Ruiz and Pérez-Belmonte. | ||
| 520 | |a Objectives: To investigate the use of once-weekly semaglutide in a real population of people with type 2 diabetes mellitus (T2DM) in three Spanish hospitals | ||
| 520 | |a Method: An observational, retrospective and multicenter clinical study was designed that included 166 participants with T2DM, distinguishing between a group naïve to GLP-1RA (n=72) and another switching from another GLP-1RA (n=94), all managed in the outpatient clinical setting. The primary endpoint was the change in HbA1c from baseline to the end of the study. The secondary endpoints included changes in body weight and the proportion of people with T2DM, achieving HbA1c <7.0% and body weight loss >5% | ||
| 520 | |a Results: After 24 months of follow-up, the reductions in HbA1c were -0.91 ± 0.7% (p<0.001) in the total cohort, -1.13 ± 1.38% (p<0.019) for GLP-1RA-naïve participants, and -0.74 ± 0.9% (p<0.023) for GLP-1RA-experienced participants. Body weight reductions were -12.42 ± 9.1% in GLP-1RA-naïve participants vs. -7.65 ± 9.7% in GLP-1RA-experienced participants (p<0.001). In the total cohort, 77.1% reached the objective of an HbA1c level <7%, and 12.7% reached between 7.1% and 7.5%. Additionally, 66.9% achieved a weight reduction ≥5%. Of all cohort, 90% received 1 mg of semaglutide once a week. The reported adverse events were consistent with the known safety profile of semaglutide | ||
| 520 | |a Conclusions: In routine clinical practice in Spain, the use of semaglutide once a week was associated with statistically significant and clinically relevant improvements in HbA1c and body weight in a wide range of adults with T2DM, without notable adverse effects, which supports real-world use | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a HbA1c | |
| 650 | 4 | |a T2DM | |
| 650 | 4 | |a body weight | |
| 650 | 4 | |a once-weekly semaglutide | |
| 650 | 4 | |a real-world use | |
| 650 | 7 | |a Glycated Hemoglobin A |2 NLM | |
| 650 | 7 | |a Hypoglycemic Agents |2 NLM | |
| 650 | 7 | |a semaglutide |2 NLM | |
| 650 | 7 | |a 53AXN4NNHX |2 NLM | |
| 650 | 7 | |a Glucagon-Like Peptides |2 NLM | |
| 650 | 7 | |a 62340-29-8 |2 NLM | |
| 700 | 1 | |a Miramontes-González, Jose Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Avilés-Bueno, Beatriz |e verfasserin |4 aut | |
| 700 | 1 | |a Jiménez-Millán, Ana Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Rivas-Ruiz, Francisco |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Belmonte, Luis M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in endocrinology |d 2010 |g 13(2022) vom: 27., Seite 995646 |w (DE-627)NLM208813357 |x 1664-2392 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2022 |g day:27 |g pages:995646 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fendo.2022.995646 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2022 |b 27 |h 995646 | ||